Stockreport

Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview
PDF -- Statistically Significant Improvements in MRI T2 Rate of Change Compared to Control Consistent with Improvements Demonstrated in Assessments of Muscle [Read more]